Related references
Note: Only part of the references are listed.JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Lucas Walz et al.
BMC INFECTIOUS DISEASES (2021)
Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action
Melanie M. Taylor et al.
LANCET GLOBAL HEALTH (2021)
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Phillip D. Monk et al.
LANCET RESPIRATORY MEDICINE (2021)
A novel coronavirus outbreak of global health concern
Chen Wang et al.
LANCET (2020)
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Yixuan J. Hou et al.
CELL (2020)
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Carly G. K. Ziegler et al.
CELL (2020)
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhuo Zhou et al.
CELL HOST & MICROBE (2020)
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19
Annsea Park et al.
CELL HOST & MICROBE (2020)
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019
Thomas R. O'Brien et al.
CLINICAL INFECTIOUS DISEASES (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Interferon beta-1b for COVID-19
Sarah Shalhoub
LANCET (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
Interferon-α2b Treatment for COVID-19
Qiong Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
Antiviral activities of type I interferons to SARS-CoV-2 infection
Emily Mantlo et al.
ANTIVIRAL RESEARCH (2020)
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Nan Wang et al.
CELL HOST & MICROBE (2020)
Presence of Genetic Variants Among Young Men With Severe COVID-19
Caspar I. van der Made et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19
Jeong Seok Lee et al.
SCIENCE IMMUNOLOGY (2020)
Effects of COVID-19 on the Nervous System
Costantino Iadecola et al.
CELL (2020)
Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review
Thomas S. Higgins et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2020)
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Jerome Hadjadj et al.
SCIENCE (2020)
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Kumari G. Lokugamage et al.
JOURNAL OF VIROLOGY (2020)
Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor
Olusegun O. Onabajo et al.
NATURE GENETICS (2020)
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
Prabhu S. Arunachalam et al.
SCIENCE (2020)
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard et al.
SCIENCE (2020)
Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2
Hongjie Xia et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2020)
Covid-19: New coronavirus variant is identified in UK
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2020)
Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
Michael W. Russell et al.
FRONTIERS IN IMMUNOLOGY (2020)
Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
Josef Brzoska et al.
DRUG RESEARCH (2020)
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome
Uh Jin Kim et al.
ANTIVIRAL THERAPY (2016)
Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS
Imran Khalid et al.
RESPIRATORY CARE (2016)
Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
Mohammed Al Ghamdi et al.
BMC INFECTIOUS DISEASES (2016)
Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013
Asim Malik et al.
EMERGING INFECTIOUS DISEASES (2016)
Ribavirin and interferon-alpha 2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
Mohammed Khalid et al.
ANTIVIRAL THERAPY (2015)
Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
Mohammad Khalid et al.
ANNALS OF SAUDI MEDICINE (2014)
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
Jaffar A. Al-Tawfiq et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
Ali S. Omrani et al.
LANCET INFECTIOUS DISEASES (2014)
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
Kyoung Song et al.
PLOS ONE (2014)
Innate Immune Response of Human Alveolar Type II Cells Infected with Severe Acute Respiratory Syndrome-Coronavirus
Zhaohui Qian et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2013)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2012)
Current and emerging therapies in multiple sclerosis: a systematic review
Wanda Castro-Borrero et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
Z Zhao et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2003)
Treatment of SARS with human interferons
J Cinatl et al.
LANCET (2003)
Share Paper
